Drugs / CTX112
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06925542 | Mar 2025 → Dec 2031 expected | diffuse cutaneous systemic sclerosis, idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus | CRISPR Therapeutics AG | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07549698 | Jun 2026 → Dec 2033 expected | autoimmune hemolytic anemia, warm type, autoimmune thrombocytopenic purpura | CRISPR Therapeutics AG | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05643742 | Mar 2023 → Jan 2030 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma +1 | CRISPR Therapeutics AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | CRISPR Therapeutics | Results CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies crisprtx.com ↗
Single-agent activity with zugo-cel demonstrated an overall response rate (ORR) of 90% (9/10) and a complete response rate (CRR) of 70% (7/10) in patients dosed at the 600 million cell dose, with 67% (2/3) of patients in complete response (CR) after one year on study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) |
| 2024-12-09 | CRISPR Therapeutics | Results CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting crisprtx.com ↗
These preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile. |
| 2023-12-04 | CRISPR Therapeutics | Results CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease crisprtx.com ↗
Preliminary data from ongoing clinical trials of its next-generation candidates, CTX112 targeting CD19 and CTX131 targeting CD70, suggest that these candidates may improve upon that clinical profile. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-02 | CRISPR Therapeutics | CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 crisprtx.com ↗ |
| 2025-12-22 | CRISPR Therapeutics | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies crisprtx.com ↗ |
| 2024-12-09 | CRISPR Therapeutics | CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting crisprtx.com ↗ |
| 2023-12-04 | CRISPR Therapeutics | CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease crisprtx.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05643742 ↗ |
| Known as | zugo-cel | “This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in...” NCT07549698 ↗ |
| Known as | Zugocabtagene geleucel | “This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in...” NCT07549698 ↗ |
| Modality | Cell therapy | “T-cell immunotherapy” NCT05643742 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT05643742 ↗ |
| Target | CD19 | “CD19-directed” NCT05643742 ↗ |